|
1
|
Li Z and Jin Z: Comparative effect and
safety of verapamil in keloid and hypertrophic scar treatment: A
meta-analysis. Ther Clin Risk Manag. 12:1634–1641. 2016. View Article : Google Scholar
|
|
2
|
Xue M and Jackson CJ: Extracellular matrix
reorganization during wound healing and its impact on abnormal
scarring. Adv Wound Care (New Rochelle). 4:119–136. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wilgus TA and Wulff BC: The importance of
mast cells in dermal scarring. Adv Wound Care (New Rochelle).
3:356–365. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Younai S, Nichter LS, Wellisz T, Reinisch
J, Nimni ME and Tuan TL: Modulation of collagen synthesis by
transforming growth factor-beta in keloid and hypertrophic scar
fibroblasts. Ann Plast Surg. 33:148–151. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Suarez E, Syed F, Rasgado TA, Walmsley A,
Mandal P and Bayat A: Skin equivalent tensional force alters keloid
fibroblast behavior and phenotype. Wound Repair Regen. 22:557–68.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sonkoly E, Stahle M and Pivarcsi A:
MicroRNAs: Novel regulators in skin inflammation. Clin Exp
Dermatol. 33:312–315. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Igoucheva O and Alexeev V:
MicroRNA-dependent regulation of cKit in cutaneous melanoma.
Biochem Biophys Res Commun. 379:790–794. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Molnar V, Tamasi V, Bakos B, Wiener Z and
Falus A: Changes in miRNA expression in solid tumors: An miRNA
profiling in melanomas. Semin Cancer Biol. 18:111–122. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mottamal M, Zheng S, Huang TL and Wang G:
Histone deacetylase inhibitors in clinical studies as templates for
new anticancer agents. Molecules. 20:3898–3941. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Schneider MR: MicroRNAs as novel players
in skin development, homeostasis and disease. Br J Dermatol.
166:22–28. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhao LM and Zhang JH: Histone deacetylase
inhibitors in tumor immunotherapy. Curr Med Chem. 2017.(Epub ahead
of prin). View Article : Google Scholar
|
|
13
|
Singh A, Patel P, Jageshwar, Patel VK,
Jain DK, Kamal M and Rajak H: The safety, efficacy and therapeutic
potential of histone deacetylase inhibitors with special reference
to panobinostat in gastrointestinal tumors: A Review of Preclinical
and Clinical Studies. Curr Cancer Drug Targets. 18:720–736. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yang L, Qu M, Wang Y, Duan H, Chen P, Wang
Y, Shi W, Danielson P and Zhou Q: Trichostatin a inhibits
transforming growth Factor-β induced reactive oxygen species
accumulation and myofibroblast differentiation via enhanced
NF-E2-related factor 2-antioxidant response element signaling. Mol
Pharmacol. 83:671–680. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rao X, Huang X, Zhou Z and Lin X: An
improvement of the 2ˆ(-delta delta CT) method for quantitative
real-time polymerase chain reaction data analysis. Biostat
Bioinforma Biomath. 3:71–85. 2013.PubMed/NCBI
|
|
17
|
Rhodes LV, Nitschke AM, Segar HC, Martin
EC, Driver JL, Elliott S, Nam SY, Li M, Nephew KP, Burow ME and
Collins-Burow BM: The histone deacetylase inhibitor trichostatin A
alters microRNA expression profiles in apoptosis-resistant breast
cancer cells. Oncol Rep. 27:10–16. 2012.PubMed/NCBI
|
|
18
|
Williams SM, Golden-Mason L, Ferguson BS,
Schuetze KB, Cavasin MA, Demos-Davies K, Yeager ME, Stenmark KR and
McKinsey TA: Class I HDACs regulate angiotensin II-dependent
cardiac fibrosis via fibroblasts and circulating fibrocytes. J Mol
Cell Cardiol. 67:112–125. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bodas M, Mazur S, Min T and Vij N:
Inhibition of histone-deacetylase activity rescues inflammatory
cystic fibrosis lung disease by modulating innate and adaptive
immune responses. Respir Res. 19:22018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xu X, Jin S, Ma Y, Fan Z, Yan Z, Li W,
Song Q, You W, Lyu Z and Song Y: miR-30a-5p enhances paclitaxel
sensitivity in non-small cell lung cancer through targeting BCL-2
expression. J Mol Med (Berl). 95:861–871. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tung CW, Hsu YC, Cai CJ, Shih YH, Wang CJ,
Chang PJ and Lin CL: Trichostatin A ameliorates renal
tubulointerstitial fibrosis through modulation of the JNK-dependent
Notch-2 signaling pathway. Sci Rep. 7:144952017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kaimori A, Potter JJ, Choti M, Ding Z,
Mezey E and Koteish AA: Histone deacetylase inhibition suppresses
the transforming growth factor beta1-induced
epithelial-to-mesenchymal transition in hepatocytes. Hepatology.
52:1033–45. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rombouts K, Niki T, Greenwel P,
Vandermonde A, Wielant A, Hellemans K, De Bleser P, Yoshida M,
Schuppan D, Rojkind M and Geerts A: Trichostatin A, a histone
deacetylase inhibitor, suppresses collagen synthesis and prevents
TGF-beta(1)-induced fibrogenesis in skin fibroblasts. Exp Cell Res.
278:184–197. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sun J, Wang Y, Cui W, Lou Y, Sun G, Zhang
D and Miao L: Role of epigenetic histone modifications in diabetic
kidney disease involving renal fibrosis. J Diabetes Res. 7:242–384.
2017.
|
|
25
|
Ghosh AK, Mori Y, Dowling E and Varga J:
Trichostatin A blocks TGF-beta-induced collagen gene expression in
skin fibroblasts: involvement of Sp1. Biochem Biophys Res Commun.
354:420–426. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Diao JS, Xia WS, Yi CG, Wang YM, Li B, Xia
W, Liu B, Guo SZ and Sun XD: Trichostatin A inhibits collagen
synthesis and induces apoptosis in keloid fibroblasts. Arch
Dermatol Res. 303:573–580. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Babalola O, Mamalis A, Lev-Tov H and
Jagdeo J: The role of microRNAs in skin fibrosis. Arch Dermatol
Res. 305:763–76. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhu H, Han C and Wu T: MiR-17-92 cluster
promotes hepatocarcinogenesis. Carcinogenesis. 36:1213–22. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dakhlallah D, Batte K, Wang Y,
Cantemir-Stone CZ, Yan P, Nuovo G, Mikhail A, Hitchcock CL, Wright
VP, Piper MG and Marsh CB: Epigenetic regulation of miR-17~92
contributes to the pathogenesis of pulmonary fibrosis. Am J Respir
Crit Care Med. 187:397–405. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li YL, Wang J, Zhang CY, Shen YQ, Wang HM,
Ding L, Gu YC, Lou JT, Zhao XT, Ma ZL and Jin YX: MiR-146a-5p
inhibits cell proliferation and cell cycle progression in NSCLC
cell lines by targeting CCND1 and CCND2. Eur Respir J.
7:59287–59298. 2016.
|
|
31
|
He R, Yang L, Lin X, Chen X, Lin X, Wei F,
Liang X, Luo Y, Wu Y, Gan T, et al: MiR-30a-5p suppresses cell
growth and enhances apoptosis of hepatocellular carcinoma cells via
targeting AEG-1. Int J Clin Exp Pathol. 8:15632–15641.
2015.PubMed/NCBI
|
|
32
|
Wang Z, Dai X, Chen Y, Sun C, Zhu Q, Zhao
H, Liu G, Huang Q and Lan Q: MiR-30a-5p is induced by Wnt/β-catenin
pathway and promotes glioma cell invasion by repressing NCAM.
Biochem Biophys Res Commun. 465:374–380. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Safaeian L, Abed A and Vaseghi G: The role
of Bcl-2 family proteins in pulmonary fibrosis. Eur J Pharmacol.
741:281–9. 2014. View Article : Google Scholar : PubMed/NCBI
|
